期刊
ACS CHEMICAL NEUROSCIENCE
卷 5, 期 12, 页码 1253-1265出版社
AMER CHEMICAL SOC
DOI: 10.1021/cn500201x
关键词
Casein kinase 1; CK1 delta; CK1 epsilon; PF-5006739; dual inhibitor; circadian rhythm; phase-delaying; opioid reinstatement; drug addiction
Casein kinase 1 delta (CK1 delta) and casein kinase 1 epsilon (CK1 epsilon) inhibitors are potential therapeutic agents for a range of psychiatric disorders. The feasibility of developing a CNS kinase inhibitor has been limited by an inability to identify safe brain-penetrant compounds with high kinome selectivity. Guided by structure-based drug design, potent and selective CK1 delta/epsilon inhibitors have now been identified that address this gap, through the design and synthesis of novel 4-[4-(4-fluoropheny1)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine derivatives. PF-5006739 (6) possesses a desirable profile, with low nanomolar in vitro potency for CK1 delta/epsilon (IC50 = 3.9 and 17.0 nM, respectively) and high kinome selectivity. In vivo, 6 demonstrated robust centrally mediated circadian rhythm phase-delaying effects in both nocturnal and diurnal animal models. Further, 6 dose-dependently attenuated opioid drug-seeking behavior in a rodent operant reinstatement model in animals trained to self-administer fentanyl. Collectively, our data supports further development of 6 as a promising candidate to test the hypothesis of CK1 delta/epsilon inhibition in treating multiple indications in the clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据